CGIX Cancer Genetics Inc

Glancy Prongay & Murray LLP Continues Investigation on Behalf of Cancer Genetics, Inc. Investors (CGIX)

LOS ANGELES--(BUSINESS WIRE)--

Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Cancer Genetics, Inc. (“Cancer Genetics” or the “Company) (NASDAQ: CGIX) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Cancer Genetics investigation page on our website at www.glancylaw.com/case/cancer-genetics-inc.

On April 2, 2018, the Company reported that following the departure of its former CEO, it undertook a “comprehensive and extensive review” of its strategy and organization. As a result, the Company recorded a bad debt expense of $4.4 million and wrote off $1.8 million of its accounts receivable in the fourth quarter of 2017, largely related to “collection issues” with respect to the accounts receivable recorded subsequent to the Company’s 2015 acquisition of Response Genetics Inc. The Company further disclosed that it “had a Material Weakness in Internal Controls Over Financial Reporting at December 31, 2017” and that its 2017 annual report would contain a going concern qualification.

On this news, Cancer Genetics’ share price fell $0.55 per share, or 33.3%, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased Cancer Genetics securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
06/04/2018

Underlying

CGIXCancer Genetics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cancer Genetics Inc

 PRESS RELEASE
Free
CGIX Cancer Genetics...

Vyant Bio Provides Update on Winddown Activities

Vyant Bio Provides Update on Winddown Activities CHERRY HILL, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its Plan of Liquidation and Dissolution following the sale of substantially all of its assets. Vyant Bio’s Board of Directors currently anticipates that it will file a Certificate of Dissolution with the State of Delaware in late December 2023, after which the Company’s common stock will cease to trade and holders of shares of the Company’s common sto...

November 10, 2023 1 EN
 PRESS RELEASE
Free
CGIX Cancer Genetics...

Vyant Bio Announces Stockholder Approval of Plan of Dissolution

Vyant Bio Announces Stockholder Approval of Plan of Dissolution CHERRY HILL, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is announcing the results of its special meeting of stockholders on November 1, 2023 (the “Special Meeting”). At the Special Meeting, Vyant Bio’s stockholders, upon the unanimous recommendation of Vyant Bio’s board of directors, voted in favor of the proposal to approve the voluntary liquidation and dissolution of the Company, pursuant to a Plan of Liquidation and Dissolution (the “Dissolution Proposal). The proposal r...

November 1, 2023 1 EN
 PRESS RELEASE
Free
CGIX Cancer Genetics...

Vyant Bio Announces Completion of StemoniX Asset Sale

Vyant Bio Announces Completion of StemoniX Asset Sale CHERRY HILL, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) announced that it has completed the sale of all or substantially all of the assets of the Company (the “Sale”) pursuant to an Asset Purchase Agreement dated July 13, 2023. ABOUT VYANT BIO, INC. Vyant Bio, Inc. (OTC: VYNT) has no continuing operating activities other than the winddown and closure of its business. The Company is currently seeking to obtain its shareholders’ approval for the voluntary liquidation and dissolution o...

October 24, 2023 1 EN
 PRESS RELEASE
Free
CGIX Cancer Genetics...

Vyant Bio Announces Stockholder Approval of Proposed Asset Sale; 64,11...

Vyant Bio Announces Stockholder Approval of Proposed Asset Sale; 64,110 Votes Needed to Approve Plan of Dissolution; and Adjournment of Special Meeting of Stockholders CHERRY HILL, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) announced that its special meeting of stockholders on October 19, 2023 (the “Special Meeting”) was reconvened resulting in the approval of the sale of all or substantially all of the assets of the Company. At the Special Meeting, Vyant Bio’s stockholders, upon the unanimous recommendation of Vyant Bio’s board of ...

October 19, 2023 1 EN
 PRESS RELEASE
Free
CGIX Cancer Genetics...

Vyant Bio Announces 77,522 Votes Needed to Approve Sale of Assets 175,...

Vyant Bio Announces 77,522 Votes Needed to Approve Sale of Assets 175,721 Votes Needed to Approve Winddown of Business Adjournment of Special Meeting of Stockholders CHERRY HILL, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 28, 2023 (the “Special Meeting”) was reconvened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposals as described in the Company’s definitive proxy statement filed...

October 11, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch